Status:
COMPLETED
Prevalence of Exocrine Pancreatic Insufficiency in Patients With Decompensated Cirrhosis
Lead Sponsor:
Corporacion Parc Tauli
Conditions:
Exocrine Pancreatic Insufficiency
Eligibility:
All Genders
18-85 years
Brief Summary
Exocrine pancreatic insufficiency (EPI) is the inability of the pancreas to perform a normal digestive function. The prevalence of IPE in patients with decompensated hepatic cirrhosis (HC) is unknown ...
Detailed Description
Exocrine pancreatic insufficiency (EPI) is defined as the inability of the pancreas to perform a normal digestive function. Habitually, it occurs as a result of a severe reduction in the secretion of ...
Eligibility Criteria
Inclusion
- Patients with histological diagnosis of CH or by clinical, analytical, ecographic or fibroscan criteria.
- Patients with decompensated HC (ascites, hepatic hydrothorax, hepatorenal syndrome, digestive bleeding due to portal hypertension or hepatic encephalopathy.
- Signature of informed consent
- Prevision of hospital admission for a minimum of 48 hours (for the correct completion of the marked triolein test and the collection of samples for fecal elastase)
- Age between 18 and 85 years.
Exclusion
- Previous diagnosis of EPI
- Suspected biliary tract obstruction
- Need for high doses of laxative which makes it impossible to collect faecal samples correctly (\> 5 dep / d secondary to laxatives)
- Patients who, due to their clinical situation, are unable to collaborate in the labeled triolein breath test
- Patients with inability to use the oral route.
Key Trial Info
Start Date :
October 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT03236038
Start Date
October 1 2017
End Date
December 31 2019
Last Update
December 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Parc Tauli Hospital
Barcelona, Spain, 28208